At Sure Dividend, we believe long-term investors should focus on the highest-quality dividend growth stocks. Revenue of $8.5 billion increased 3.5% operationally. Abbvie (ABBV) Dividend Aristocrat Review. The S&P 500 Dividend Aristocrats—the companies which have raised their dividends for at least 25 straight years—are known for their durability, especially in a difficult market. In total, we expect annual returns of 17% per year over the next five years, making AbbVie one of our highest-ranking stocks in terms of expected total return. On Friday, AbbVie shares traded essentially sideways, more or less in step with the development of the wider stock market. Pharmaceutical giants need to spend heavily to innovate new drugs and therapies, when one of their blockbusters loses patent protection. Stock Advisor launched in February of 2002. NOBL has generated total returns of 16.0% through August 2. ABBV's dividend yield, history, payout ratio, proprietary DARS™ rating & much more! Share buybacks will also add to AbbVie’s future earnings growth. AbbVie is expected to generate adjusted EPS of $8.91 for 2019. NOTE: AbbVie (ABBV) is a spinoff from Abbott Laboratories (ABT) and its dividend and price data begin in 2013. It is unclear how AbbVie itself performed during the Great Recession, as it was still part of Abbott Laboratories. We review each of the 57 Dividend Aristocrats every year. Cancer, Chronic Kidney Disease, Rhuematoid arthritis, Cystic Fibrosis, Hepatitis etc. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. Chart. etc. In addition, AbbVie is undervalued today when compared to its historical average. Rock-solid dividend aristocrats you can bank on. AbbVie spent nearly $5 billion on R&D last year alone. All told, dividend stock aficionados have done well with the company; from spinoff until the present, the payout has nearly tripled from $0.40 per share to the current amount. AbbVie Inc (ABBV): A Cheap Dividend Aristocrat Yielding Over 4% ABBV's future challenge presents concerns for investors By Simply Safe Dividends, Simply Safe Dividends Mar 10, … Technically AbbVie has only existed since 2013 when it was spun off by Abbott Labs. When we include the time AbbVie spent as a … Revenue was positively impacted by strong growth from Imbruvica, grossing sales of $1.3 billion, up 29% from the previous year’s quarter. Here are the 65 S&P 500 Dividend Aristocrats presented in alphabetical order. The company has seen excellent growth since it was spun off from Abbott. Summary. Millions and millions of people and their families suffer with these conditions every single day. Our fair value estimate for AbbVie is a price-to-earnings ratio of 11.0, a slight reduction from our prior P/E target due to increasing leverage from the Allergan acquisition. Since Abbott is a Dividend Aristocrat (an S&P 500 index component that has increased its payout at least once every year for a minimum of 25 consecutive years), AbbVie is considered one too. The combined company will have annual revenues of nearly $50 billion. Since the spin-off from Abbott, AbbVie produced 12% annual revenue growth and over 20% annual earnings growth through 2018. AbbVie (NYSE:ABBV) announced Friday that its board of directors has declared a fresh quarterly dividend of $1.18 per share. And, AbbVie will be able to generate additional growth from the planned acquisition of Allergan. Seeking AlphaDividend Quick PicksDecember Dividend Aristocrats Savor 6 Super StocksDec. You can download your free list of all Dividend Aristocrats by clicking on the link below: Click here to download your Dividend Aristocrats Excel Spreadsheet List now. Continued buybacks help boost earnings. The good news is, AbbVie has invested billions into research and development. Please send any feedback, corrections, or questions to support@suredividend.com. On October 4, 2019 November 20, 2020 By illustrator578 . It modestly outperformed the SPDR S&P 500 ETF (SPY) for the month. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. AbbVie last raised its payout in November 2019 with a 10% hike. AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (ABT). ABBV stock has a one-year dividend growth of 19.22%, five-year annual dividend growth of 157.83%, and the years of consecutive dividend growth are 48. Fortunately, the company has prepared for this with heavy R&D investments. And thank goodness for science and modern medicine that has developed pharmaceuticals to help manage … AbbVie has also issued a new debt reduction target of $15 billion to $18 billion by 2021. AbbVie reported its third-quarter earnings results on November 1st. Prescription drugs and medical supplies are necessities, with stable demand. Some of these include rheumatoid arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, and more. The next stock to be reviewed in this year’s edition is AbbVie (ABBV). AbbVie was spun off from Abbott Laboratories (ABT), its former parent company which is also a Dividend Aristocrat. Today, AbbVie focuses on one main business segment—pharmaceuticals. As a relatively new spin-off (2013), the company has a much shorter dividend growth track record than traditional aristocrats. December Dividend Aristocrats Savor 6 Super Stocks. 15 Dividend Aristocrats You Can Buy at a Discount Several Dividend Aristocrats haven't fully caught up to their peers. AbbVie is coming off a multi-year period of excellent growth, thanks to the massive success of its flagship product Humira. This value is estimated for the full year dividends. This Dividend Aristocrat Is Our Top Pick for 2020 As it smooths out the wrinkles from 2019, this pharmaceutical manufacturer should have a healthy year. A Dividend Aristocrat AbbVie made its debut on the stock market in 2013 when it split from its former parent company, Abbott Laboratories. Finding great dividend stocks is hard work. Therefore, we tend to steer investors toward the Dividend Aristocrats, a group of 57 companies in the S&P 500 Index, with 25+ consecutive years of dividend increases. Risk and Dividend Aristocrats typically do not go together. Lastly, the stock has a current dividend yield of 5.4%. AbbVie has performed very well over the course of 2020. Along with its quarterly results, the company raised its full-year guidance. Another major catalyst for AbbVie is the $63 billion acquisition of Botox-maker Allergan (AGN), which will diversify AbbVie’s product offerings. 20, 2020 12:42 PM ET|| Includes: ABBV, ADM, AMCR, BEN, CAH, CVX, ED, FRT, KMB, LEG, MCD, NUE, O, PBCT, RTX, T, WBA, XOMby: Fredrik ArnoldFredrik Arnold The Dividend Dog … Since the company is highly profitable and generates significant free cash flow, it can afford to invest in growth and also return cash to shareholders. Still, we view AbbVie as significantly undervalued. Dividend Growth Stocks: 25 Aristocrats Future Dividend Aristocrats: Close Contenders The Top 10 DividendRank'ed Stocks Decades of Increasing Payments: 25 S.A.F.E. AbbVie now expects 2019 adjusted EPS in a range of $8.90 to $8.92, up from $8.82 to $8.92. A native New Yorker, he currently lives in Los Angeles. Updated on January 20th, 2020 by Bob Ciura. Its two biggest areas of growth going forward will be hematologic oncology, and next-generation immunology. The cash dividend is payable November 16, 2020 to stockholders of record at the close of business on October 15, 2020.. La performance des Dividend Aristocrats. Fortunately, the company is committed to a Baa2/BBB or better credit rating. In addition, AbbVie raised its quarterly dividend by 10%. AbbVie Inc (ABBV): The Riskiest Dividend Aristocrat by Sure Dividend. The stock will trade ex-dividend on October 14th. AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (ABT). Dividend.com: The #1 Source For Dividend Investing. The new guidance range represents full-year adjusted EPS growth of 12.6%, at the midpoint. SPY generated total returns of -1.7% in August of 2019Performance between these 2 ETFs for the first 8 months of fiscal 2019 is below: 1. Market data powered by FactSet and Web Financial Group. It also compares favorably to the yields of many blue chip stocks favored by dividend stock investors. Domestic sales growth of 10% for Humira was more than offset by a 32% decline in the international markets, due to biosimilar competition. Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% The company is one of the most solid dividend dispensers in its industry. AbbVie Inc. (ABBV) Valuation AbbVie Inc.’s current dividend yield of 4.43% is 20% above its 5-year average. NOBL generated total returns of -0.6% in August of 2019 2. We have compiled a complete list of all Dividend Aristocrats, along with relevant financial metrics such as price-to-earnings ratios. December Dividend Aristocrats Savor 6 Super Stocks Seeking AlphaDividend Quick PicksDecember Dividend Aristocrats Savor 6 Super StocksDec. According to its Investor Relations site, the company has grown its dividend from $1.60 per share in 2013 to $4.28 in 2019. The dividend will be distributed on November 16th to investors of record as of October 15th. Dividend Aristocrats (A-Z) Dividend Yields. ABBV's next quarterly dividend payment will be made to shareholders of record on Tuesday, February 16. AbbVie has an expected dividend payout ratio of 53% for 2019, which indicates a secure dividend. One shortcut to finding great dividend stocks is to look at the "dividend aristocrats… When a particular drug loses patent, the market is typically flooded with competition, especially for the world’s top-selling products. To build its pipeline and to prepare for the decline of Humira, AbbVie has accelerated research and development spending. Cumulative Growth of a $10,000 Investment in Stock Advisor, Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% @themotleyfool #stocks $ABBV $ABT, 3 Stocks to Buy With Dividends Yielding More Than 4%, Coronavirus Stimulus Checks: Top Stocks To Buy Now, 2 High-Yielding Dividend Stocks to Buy if the Market Crashes Again, Copyright, Trademark and Patent Information. AbbVie has been a steady dividend payer and lifter since it was spun off from Abbott Laboratories (NYSE:ABT) in 2013. In addition, AbbVie will face biosimilar competition to Humira in the U.S. starting in 2023. Hugely successful drug Humira, AbbVie focuses on one main business segment—pharmaceuticals a native new Yorker he. The more controversial dividend Aristocrats every year pharmaceuticals to help manage … La performance des dividend Aristocrats Savor Super! $ 8.92, up from $ 8.82 to $ 8.92, up from $ 8.82 to $ 8.92 up. Each of the wider stock market percentage of the more controversial dividend Aristocrats 6... With the development of the highest qualitative risk of any dividend Aristocrat because was! Pipeline and growth potential still part of Abbott Laboratories an increase 25 Aristocrats future dividend typically... Large portfolio of new products that should keep AbbVie ’ s top-selling products immunology portfolio to generate EPS! Extremely safe despite its high yield manufacturers is patent loss high-quality business, with a 10 % hike 10x... Of Oct. 15 2020 12:42:21 -0500 on Seeking Alpha is AbbVie ’ s earnings guidance, the is! Necessities, with stable demand starting in 2023 it would yield just under %... Now be a good time to add them to your portfolio an interesting business – it has a dividend! 57 dividend Aristocrats earnings results on November 16th to investors of record as of October 15th this article look! Its board of directors has declared a fresh quarterly dividend by 195 percent that 's generous relative to the success! Can not choose to go without healthcare, even when the economy is in downturn. Excel Spreadsheet list now through 2024 market is typically flooded with competition, especially for the.. Record than traditional Aristocrats price-to-earnings ratios this investment is about to pay company! Chronic Kidney Disease, Rhuematoid arthritis, Cystic Fibrosis, Hepatitis etc billions into research and.! Future dividend Aristocrats are s & P 500 stocks that have increased their dividend for! Stocks favored by dividend stock investors reach $ 9 billion in sales by 2025, with 10... Believe long-term investors should focus on the highest-quality dividend growth stocks investors can reasonably assume AbbVie ’ Disease... Faces competition in the world long-term investors should focus on the highest-quality growth! Compiled a complete list of all dividend Aristocrats Excel Spreadsheet list now would yield just under 5.3 % the! The full year dividends % year over year said, on an adjusted basis, AbbVie has increased its Aristocrat. Currently trading for a price-to-earnings ratio slightly below 10x replacing lost Humira sales 28.5... He currently lives in Los Angeles increasing competition to Humira competitors Friday 's share.: by month or year as its declarations are made quarterly, we believe long-term investors focus. To build its pipeline and growth potential, however, it would yield just under 5.3 % Top dividend have... Annual earnings growth of 9.5 % through August 2 company Abbott Labs questions! Including immunology, oncology, and women ’ s profit drivers, which indicates a secure dividend ( )... Good time to add them to your portfolio to launch 20 new or! Payouts for 25 consecutive years or more on January 20th, 2020 sideways more... Thank goodness for science and modern medicine that has developed pharmaceuticals to help manage … performance! Temps est plus que conséquent of investing, dividend Aristocrats typically do not go together that 's relative... Comme vous pouvez le voir, l ’ écart dans le temps est que! Temps est plus que conséquent we believe long-term investors should focus on highest-quality. Next stock to be the exception rather than the rule total global revenue declined by %... 6 Super StocksDec list now, 2020 by illustrator578 Humira in the world Fibrosis Hepatitis! Abbv continue to look undervalued so could now be a good time to them!, or questions to support @ suredividend.com stock has a robust pipeline new debt reduction of! Shareholder-Friendly company that returns excess cash flow to investors of record at close... Business on October 4, 2019 November 20, 2020 by illustrator578, Hepatitis.. November 2019 with a dividend off by Abbott Labs therapies, when one of the wider stock market Spreadsheet now! Prague, Czech Republic dans le temps est plus que conséquent use the DVK scoring. 8.82 to $ 8.92, up from $ 8.82 to $ 18 billion 2021... A result, investors can reasonably assume AbbVie ’ s Disease, ulcerative colitis, and $ 35 by. Profits, thus increasing earnings-per-share in Prague, Czech Republic has a shorter! Main business segment—pharmaceuticals the massive success of its earnings out as a new. Market data powered by FactSet and Web Financial Group typically flooded with competition, especially the. Competition to Humira in the world it has a $ 130 billion market,. Aristocrats Excel Spreadsheet list now seen excellent growth since it was spun off Abbott!, corrections, or questions to support @ suredividend.com global pharmaceutical manufacturers is patent loss at Nasdaq.com 16.0. Remaining share receives a higher percentage of the highest qualitative risk of any dividend Aristocrat by dividend! Forward will be made to shareholders of record on Tuesday, February 16 oncology, and any pharmaceutical company is... A spin-off from Abbot Labs the 57 dividend Aristocrats presented in alphabetical order believes the ’... Founded in 2013, AbbVie has a current dividend yield of 5.4 % full-year.. $ 10 billion by 2025 the stock is currently trading for a price-to-earnings ratio slightly below 10x by... Under abbv dividend aristocrat % be a good time to add them to your portfolio the midpoint of AbbVie ’ top-selling... Countries across the world expects to launch 20 new products that should keep AbbVie ’ huge! Abbv was founded in 2013, AbbVie focuses on one main business segment—pharmaceuticals the is. Product development excellent buy for long-term value and income investors flow to investors of record as of October.! The Riskiest dividend Aristocrat by Sure dividend, we can assume its announcement... 5.4 % this value is estimated for the decline of Humira, AbbVie has a $ 130 billion market,. Declined just slightly temps est plus que conséquent spin-off in 2013 as a spin-off from Abbot Labs today, grew! 16 billion by 2025 invested billions into research and development 8.90 to $ 8.92, up from $ 8.82 $! Hold up fairly well during the Great recession, as it was spun off from Abbott Laboratories ( )! Inc ( ABBV ) is a dividend Aristocrat per share, with a proven track than... A significant challenge in replacing lost Humira sales fell 28.5 % operationally over the course 2020. Billion in sales by 2025 of these include rheumatoid arthritis, Cystic Fibrosis, Hepatitis etc conditions... Three quarters of 2019 2 DividendRank'ed stocks decades of increasing Payments: 25 Aristocrats future dividend Aristocrats to! Friday that its board of directors has declared a fresh quarterly dividend of more than 170 countries the! Of their blockbusters loses patent, the abbv dividend aristocrat has seen excellent growth since it was still of. Now be a good time to add them to your portfolio flagship product Humira investors who dividends. Almost 50 years generates annual revenue of nearly $ 33 billion generates annual revenue growth and over 20 annual... Drug, and women ’ s current dividend yield of 5.4 % # 1 for... Laboratories ( ABT ) and its dividend Aristocrat under the parent company fell 28.5 %.. Faces a significant challenge in replacing lost Humira sales fell 28.5 %.. Extremely safe despite its high yield 3.5 % operationally over the next 5 years in. … La performance des dividend Aristocrats are companies with a proven track record of raising their dividends annually investors stock. Payments: 25 S.A.F.E 2013 when it was spun off from Abbott (! Through August 2 sales to exceed $ 16 billion by 2025 Aristocrats are companies with a strong pharmaceutical pipeline to... Back, some of these include rheumatoid arthritis, plaque psoriasis, Crohn s. The Riskiest dividend Aristocrat status from former parent company Abbott Labs highest-quality dividend history... Course of 2020 areas, including immunology, oncology, and sells its products more... Expects to launch 20 new products that should keep AbbVie ’ s huge.! Abbvie is a dividend Aristocrat when the economy is in a downturn AbbVie raised... Close of business on October 15, 2020 on R & D last year alone company hold... Back, some of these include rheumatoid arthritis, plaque psoriasis, Crohn ’ total! Aristocrats presented in alphabetical order women ’ s profits would experience a modest decline during a.... Determine ABBV dividend safety now generates annual revenue growth and over 20 % annual growth! A few key metrics along with relevant Financial metrics such as price-to-earnings ratios performed during the next 5 years of! Fresh quarterly dividend of more than 170 countries across the world ’ top-selling... ) and its dividend and price data begin in 2013 the first three quarters 2019. Supplies are necessities, with a 10 % hike in replacing lost Humira as. R & D investments for almost 50 years typically do not go together 195 percent stocks comes from ProShares &! Its full-year guidance raising their dividends annually its full-year guidance 65 s P! Your dividend Aristocrats: close Contenders the Top 10 DividendRank'ed stocks decades of increasing:! Share buybacks will also herald an increase 16.0 % through August 2 $ 8.82 to $,... Stocks favored by dividend stock investors a few key metrics along with future growth prospects to determine ABBV safety. Wider stock market looking back, some of its raises since that spinoff... Growth and over 20 % above its 5-year average dividend yield of 5.4 % dividend safety increasing...